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Abstract
Background: Endoscopic mucosal resection (EMR) for large colorectal polyps is in most cases the preferred
treatment to prevent progression to colorectal carcinoma. The most common complication after EMR is delayed
bleeding, occurring in 7% overall and in approximately 10% of polyps ≥ 2 cm in the proximal colon. Previous
research has suggested that prophylactic clipping of the mucosal defect after EMR may reduce the incidence of
delayed bleeding in polyps with a high bleeding risk.
Methods: The CLIPPER trial is a multicenter, parallel-group, single blinded, randomized controlled superiority study.
A total of 356 patients undergoing EMR for large (≥ 2 cm) non-pedunculated polyps in the proximal colon will be
included and randomized to the clip group or the control group. Prophylactic clipping will be performed in the
intervention group to close the resection defect after the EMR with a distance of < 1 cm between the clips. Primary
outcome is delayed bleeding within 30 days after EMR. Secondary outcomes are recurrent or residual polyps and
clip artifacts during surveillance colonoscopy after 6 months, as well as cost-effectiveness of prophylactic clipping
and severity of delayed bleeding.
Discussion: The CLIPPER trial is a pragmatic study performed in the Netherlands and is powered to determine the
real-time efficacy and cost-effectiveness of prophylactic clipping after EMR of proximal colon polyps ≥ 2 cm in the
Netherlands. This study will also generate new data on the achievability of complete closure and the effects of clip
placement on scar surveillance after EMR, in order to further promote the debate on the role of prophylactic
clipping in everyday clinical practice.
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Background
Delayed bleeding after endoscopic mucosal resection
In 2014, a national colorectal cancer screening (NCCS)
program was introduced in the Netherlands [1]. The
program is based on immunological fecal occult blood
testing (iFOBT), followed by colonoscopy after a positive
iFOBT result. During colonoscopy, the detection of colo-
rectal cancer and advanced adenomas has been found to
be 8% and 43%, respectively [2]. The treatment of ad-
vanced adenomas has resulted in a considerable spin-off
of the NCCS program.
Endoscopic mucosal resection (EMR) is a safe and
cost-effective method for resecting larger flat or sessile
adenomas in the colorectum with no signs of submuco-
sal invasion. However, delayed bleeding (DB) is the most
prevalent complication and is reported in up to 12%
after EMR. Identified risk factors of DB after EMR are
anticoagulant drug use within 7 days of the procedure
(OR 6.3; P = 0.005), polyp size and location in the colon
with a 12% incidence rate of delayed bleeding in the
cecum, 10% in the proximal ascending colon, 7% at the
hepatic flexure, and 2–3% in the left colon [3–9].
Several preventive measures have been undertaken to re-
duce post-EMR bleeding, such as coagulation of visible ves-
sels, prophylactic clipping (PC), or suturing of the EMR
resection defect. Prophylactic coagulation of visible vessels
in the resection defect has not been shown to decrease the
incidence of DB [7]. However, PC has been reported in sev-
eral studies to reduce DB especially in right sided EMR’s
for lesions sized over 2 cm [10, 11]. Theoretically, a clip ap-
plies pressure to the underlying vessels in the EMR defect
and results in increased mucosal healing [12], which may
result in a reduced DB risk. Nonetheless, studies reporting
on PC in EMR have several limitations, such as a retro-
spective design, inclusion of all sizes and types of polyps
(pedunculated/flat, right/left-sided), lack of statistical
power, and all reported studies were performed in tertiary
referral centers, thereby not representing normal daily prac-
tice. Additionally, PC will lead to increased costs of EMR
and it is unknown whether the additional costs of PC in
high-risk patients (right sided flat polyps ≥ 2 cm) will out-
weigh the benefits of PC in terms of quality of life gains
and/or cost savings related to prevention of DB [12].
Scar surveillance
After piecemeal EMR, guidelines recommend surveil-
lance colonoscopy after 6 months to evaluate the
presence of residual adenoma [13]. Nonetheless, examin-
ing post-EMR scars with white-light endoscopy alone
may miss up to 30% of recurrences revealed by random
biopsy [14, 15]. Thorough inspection of the scar area
with enhanced imaging (e.g. NBI, I-scan, etc.) is one of
the techniques to determine the presence of recurrence.
With PC, the apposition of the defect margins with
clips may cause a different appearance of the scar lead-
ing to difficulty in assessing a potential recurrence. This
clip-induced scar pattern occurs in 30% of the EMR sites
and is described as a “clip artifact”: a bumpy scar that
has a normal pit pattern and is normal on biopsy [14,
15]. The occurrence of clip artifacts may therefore in-
crease the difficulty of detecting recurrences.
Aims
We designed a nationwide randomized controlled trial
aiming to compare PC after EMR to standard EMR care
without PC for the prevention of clinically significant
DB < 30 days. In addition, we aimed to determine DB se-
verity, rates of recurrent and residual adenoma and clip




The CLIPPER trial is a nationwide multicenter random-
ized, parallel-group, patient-blinded superiority trial,
comparing prophylactic clipping after EMR to standard
care in 356 patients undergoing EMR for a non-
pedunculated polyp in the proximal colon sized 20–60
mm in 19 hospitals of the Dutch EMR Study Group in
the Netherlands. The trial will be conducted over a time
period of 3 years. The study protocol was written in ac-
cordance with the SPIRIT guidelines [16, 17].
Eligibility criteria
Patients aged ≥ 18 years undergoing EMR of a flat or ses-
sile colonic polyp (Paris classification 0-IIa/b/c, Is) meas-
uring 20–60mm and located proximal from the splenic
flexure who gave written informed consent prior to
EMR are eligible for inclusion in the study.
A subject with any of the following exclusion criteria
prior to randomization will be excluded from participa-
tion in this study:
 Pregnancy
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 Active inflammatory colonic conditions (e.g.,
inflammatory bowel disease)
 American Society of Anesthesiology (ASA) grades
IV–V
 Previous resection or attempted resection of a lesion
less than 30 days ago
 EMR for residual adenoma still in place after a
previous intervention
 > 1 lesion to be removed in the same session
 Involvement of the cecal valve or orificium of the
appendix
 Endoscopic appearance of invasive malignancy (non-
lifting Kato D, Kudo V pit pattern)
 Macroscopic non-radical resection
 Clip deployed prior to the completion of the EMR
for a perforation or a major intra-procedural bleed-
ing that cannot be treated with coagulation
Trial treatment
Standard care: no PC
Applying snare tip soft coagulation to the margins of the
post-EMR defect is often used as preventive treatment
for recurrence and may be applied at the endoscopists’
discretion. Anticoagulant use will be managed according
to the Dutch Society of Gastroenterologists guideline
2016 [18].
Intervention: PC
PC is standardized using Quick Clip Pro - Single Use
Repositionable Clips (Olympus, Japan) and is performed
in a zipper fashion (Fig. 1). Successful PC is defined as
complete closure of the resection defect with aligning
clips placed 0.5–1.0 cm apart (Figs. 1 and 2) [10, 19].
After PC, a picture of the final result is made.
All patients will receive normal standard of care in
terms of day of discharge, instructions at discharge, out-
patient clinic visits to discuss pathology reports, and
additional treatment.
Surveillance
Six months after EMR, a surveillance colonoscopy is per-
formed, during which the endoscopic characteristics of
the scar are determined by the endoscopist and biopsies
of the scar are collected to determine residual or recur-
rent adenoma. In case of an aberrant scar morphology,
multiple biopsies of the lesion are taken with a standard
biopsy forceps. Lesions suspect for adenoma will be
treated directly following the local protocol. The
resected fragments will undergo histological analysis.
Any other irregularities in and around the scar will be
biopsied separately.
Study end points
The primary outcome is the incidence of clinically sig-
nificant DB, defined as anal blood loss occurring after
the completion of the procedure necessitating emer-
gency department consultation, blood transfusion, pro-
longation of hospital stay, re-hospitalization, or re-
intervention (either repeat endoscopy, angiography or
surgery) [5, 10, 20–23]. Self-limiting bleeding managed
on an outpatient basis is not considered to be DB.
PC may improve patients’ health status, prevent ser-
ious complications of DB, reduce the demand for health-
care, and lower costs. The secondary outcomes therefore
are (1) severity of DB (see Supplementary File 1 for
definition of DB severity), (2) procedure time, (3) perfor-
ation rate, (4) EMR scar evaluation at the first
surveillance colonoscopy after 6 months, (5) adenoma
recurrence rate at 6 months, (6) health-related quality of
life, and (7) direct and indirect costs related to PC.
Sample size considerations
DB incidence after EMR in the right colon has been re-
ported to range between 7 and 12.7% after EMR [6, 7].
Based on these studies, we believe that PC after standard
EMR may be able to reduce delayed bleedings by 7.8%
(from 9.8 to 2%) in a superiority design. With a 2-sided
significance level of 5% (0.1% used as symmetric
Fig. 1 Prophylactic clip closure in a zipper fashion. a A mucosal defect after EMR. In b, two clips are placed in a zipper fashion, approximating the
defect margins. In c, clipping is complete after six clips have been placed in a zipper fashion
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stopping boundaries during the interim-analysis, and
4.9% used as nominal significance level) and power of
80%, a total of 310 patients are required. With an esti-
mated drop out of 15%, a total of 356 patients (2 × 178)
are required to demonstrate this effect.
Study withdrawal
Subjects can leave the study at any time for any reason
without any consequences. The investigator can decide
to withdraw a subject from the study for urgent medical
reasons. There will be no replacement of individual sub-
jects after withdrawal.
Assignment of interventions
Randomization and treatment allocation
Randomization will take place in a 1:1 ratio after
complete radical EMR without a clinically indicated
intraprocedural clip placement, using a web-based
randomization module (Castor EDC, Amsterdam, The
Netherlands). Participants are stratified by center with
random block sizes of 2, 4, and 6 per stratum. A time
schedule for the trial can be found in Table 1.
Blinding
Patients will be blinded for treatment allocation
whenever possible. However, patients undergoing
EMR under conscious sedation cannot be blinded for
treatment allocation. Whereas treating physicians can-
not be blinded, the Outcome Adjudication Committee
(OAC) evaluating the endpoints will be blinded for
treatment allocation.
Data collection and management
Coded study data will be collected in a web-based case
record form (CRF) in Castor EDC. Patients will have the
option to fill out the questionnaires with the end-to-end
encrypted mobile “Improve” app (Open HealthHub,
Utrecht, The Netherlands). After the data collection is
complete, data are locked and saved for 15 years accord-
ing to national law and regulations.
Missing data within a complete follow-up term will be
prevented as much as possible. The reason for missing
data will be reported. In case of > 5% non-selective miss-
ing data, multiple imputation may be performed. Sensi-
tivity analyses will be performed with a different
assumption for the distribution of the missing data than
that was used in the primary analysis [24, 25].
Statistical analysis methods
Primary analysis
Comparison of the primary endpoint DB will be per-
formed according to intention-to-treat, using a mixed
model regression analysis to correct for clustering of
data, resulting in an estimated relative risk and 95%
Fig. 2 EMR defects with prophylactic clip closure. a A mucosal defect after EMR. In b, the EMR defect from A has been approximated with three
clips. c Another mucosal defect after EMR. In d, the EMR defect from c has been closed with four clips
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confidence intervals. Scale variables will be presented as
mean ± standard deviation and in case of skewed distri-
butions as median and range. Values will be compared
by Student’s T test, Wilcoxon rank sum test, χ2 test, or
Fisher exact test as appropriate. A two-tailed p value <
0.05 is considered statistically significant. A type 1 error
will be controlled for by only taking one presentation of
the primary endpoint (DB) per patient in the statistical
analysis. In case of multiple presentations for bleeding,
the highest gradation for severity will be included in the
analysis. The outcomes of the intention-to-treat analysis
will be compared to an exploratory per-protocol
analysis.
In case of disbalances in baseline characteristics, po-
tential confounders for DB will be determined with a χ2
test or unpaired t test where appropriate. Correction for
potential confounders with a p ≤ 0.15 will be performed
using multiple regression analysis. Considering the ex-
pected incidence of DB, the statistical power will allow
to correct for two confounding factors. We expect at
least anticoagulant medication to be a potential con-
founder for DB.
Analyses of secondary outcomes
The secondary endpoints will be compared between
study groups using Student’ T test or χ2 test whenever
appropriate. Lastly, a cost-effectiveness analysis will be
performed. As a societal perspective allows for a more
complete economic evaluation as compared to a health
care perspective alone, three cost categories will be ana-
lyzed: direct medical costs, direct non-medical costs, and
indirect costs (see Supplementary File 1 for a definition
of these secondary endpoints).
Economic evaluation
All costs will be estimated in accordance with Dutch
guidelines concerning cost-effectiveness studies [26,
27]. The price of clipping will be calculated based on
the price of the Quick Clip Pro - Single Use Reposi-
tionable Clip (Olympus, Japan) in the Netherlands.
Health care cost utilization and productivity losses
will be estimated based on customized versions of the
standardized questionnaires iMTA MCQ (Medical
Cost Questionnaire) and iMTA PCQ (Productivity
Cost Questionnaire). Loss of paid and unpaid work
will be valued by means of the friction cost approach.
Complete costs will be calculated for individual pa-
tients by multiplying actual health care resource use
and unit prices [28, 29] and will be compared directly
between study groups.
The impact of morbidity on the quality of life of pa-
tients will be assessed by the EQ-5D questionnaire. The
individual scored items will be valued by the Dutch tar-
iff. Health Utility Index scores will be used to derive a
quality-adjusted life year (QALY) estimate for each pa-
tient [30, 31]. Incremental cost-effectiveness and cost-
utility ratios will be calculated to reflect the extra costs
per patient with poor outcome prevented and the extra
costs per additional QALY respectively. Uncertainty in
the cost-effectiveness ratio will be presented non-
parametrically using bootstrap techniques. If correction
for baseline disbalances is needed, regression techniques
including bootstrapping will be used with the Net Mon-
etary Benefit as outcome parameter. Results will be
shown graphically by means of a cost-utility plane and
cost-effectiveness acceptability curves with varying
values of willingness-to-pay up to €80.000.
Table 1 Schedule of enrolment, interventions, and assessments
Study period
Enrolment Allocation Post-allocation Close-out






PC post EMR X
Questionnaires (EQ-5D, iMCQ, iPCQ) X X X X
Control group without PC X
Assessments:
Collect baseline and procedure variables X X X
Collect primary outcome variables X X
Standard of care surveillance colonoscopy X
Collect secondary outcome variables X X
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Monitoring
Data monitoring
According to the Dutch Federation of Universities
(NFU) standard for risk assessment and monitoring, the
trial was graded as having a negligible risk for partici-
pants. Therefore, no Data Safety Monitoring Board or
Data Monitoring Committee was indicated. Nonetheless,
a blinded OAC comprising 3–4 independent gastroen-
terologists will assess and weigh all severe adverse events
after completion of the trial and decide whether these
concord with definitions of the study endpoints. Using
primary source data and blinded for treatment allocation
(if possible), each member of the committee will indi-
vidually evaluate the disease course of each patient. Dis-
agreements will be resolved at a plenary consensus
meeting. Only after consensus has been reached on each
individual endpoint, a final analysis will be performed.
Harms
All adverse events will be reported to the study coordin-
ator regardless of a supposed relation to the trial inter-
vention, who will in turn report all deaths and serious
adverse events to the Central Committee on Research
involving Human Subjects (CCMO) according to Dutch
rules and legislation.
Being the primary outcome measure, DB was
exempted of this reporting obligation. The relationship
of all adverse events to the study intervention will be in-
vestigated by the primary investigators and the OAC. All
adverse events will be followed until they have abated or
until a stable situation has been reached.
Auditing
Based on the NFU standard for risk assessment and
monitoring, each participating hospital will be visited by
an independent monitor/auditor to audit adherence to
the study protocol and to local research regulations.
They will ensure correct handling of data and compare a
random sample of the collected data to their source
documents.
Interim analysis
An interim analysis of the primary endpoint will be per-
formed when 50% of patients (n = 178) have been ran-
domized and had 30 days of follow-up, aided by an
independent statistician. The Haybittle-Peto approach is
used to test efficacy, using symmetric boundaries at p <
0.001 to provide continuation or stopping advice. Finally,
the steering committee will decide on the continuation
of the trial.
Discussion
The CLIPPER trial has been designed to determine
whether PC is effective in preventing clinically
significant DB after EMR of large proximal colorectal
polyps. The current study design was improved by con-
sidering and discussing potential drawbacks of published
or ongoing trials with the principal investigators. The
following suggestions were made and implemented in
the CLIPPER study design:
1. Randomization after EMR. In this way, non-radical
EMRs are not included in the intervention arm and
therapeutic clipping for perforation or intraproce-
dural bleeding can be performed to the discretion
of the endoscopist without causing cross-over. The
reasons for exclusion of a non-randomized patient
after informed consent are registered [32].
2. Inclusion of patients with only one polyp, instead of
multiple, enables one to estimate the pure effect of
PC on DB and its severity [32].
3. Inclusion of only right sided polyps, which are
shown to be associated with a higher DB rate and
significant decrease of DB after PC [32, 33].
4. Inclusion of polyps sized 20–60 mm. Previous
studies have shown no effect of PC for smaller
polyps [34–36], and polyps over 60 mm were
excluded in view of feasibility of complete
closure [33].
5. Cost-effectiveness analysis. Some studies have
predicted cost-effectiveness of PC based on eco-
nomic models [37, 38]. We will analyze cost-
effectiveness based on healthcare utility question-
naires and clinical data.
6. Follow-up period of 6 months. Previous studies
have reported that clips can affect scar formation
and cause clip artifacts that can be hard to
distinguish from recurrent polyp tissue [14]. In
order to determine these late clip effects, we
included the first surveillance colonoscopy 6
months post-EMR in the follow-up period.
A potential drawback of this study is caused by the
timing of the informed consent. In Dutch daily clin-
ical practice, most polyps in the lower range of these
inclusion criteria, especially the 2–3 cm polyps, will
already be removed by EMR in the same session. As
it would neither be ethical nor feasible to approach
all colonoscopy patients for informed consent, we will
likely include more 3–6 cm lesions undergoing repeat
colonoscopy for EMR than 2–3 cm lesions. This needs
to be taken into account when interpreting our
results.
In conclusion, the CLIPPER trial is powered and
designed to determine the efficacy and effectiveness
of PC in everyday practice, in order to fill the gaps in
our understanding of the place of PC in the endos-
copy unit.
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Trial status
The first patient was randomized on May 15, 2018. To
date, 19 hospitals are open for inclusion and 217 pa-
tients have been randomized. The inclusion is slightly
below schedule, which is at least partly due to the recent
COVID-19 outbreak. Protocol version 2.2 is being used
and was approved on January 23, 2018, with an amend-
ment approved on August 23, 2018. Patient recruitment
is expected to last until mid-2021.
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The online version contains supplementary material available at https://doi.
org/10.1186/s13063-020-04996-7.
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